Business Wire

SMOORE

26.7.2022 08:55:10 CEST | Business Wire | Press release

Share
SMOORE Opens First PMTA Testing Laboratory in China

SMOORE, the world's largest vape manufacturer, today announced that is has opened China’s first non-clinical full-scale testing laboratory for Premarket Tobacco Product Applications (PMTA).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220725005966/en/

A PMTA is an application that must be reviewed and approved by the Food and Drug Administration (FDA) before a new nicotine product can be legally marketed in the United States. It must also provide scientific data that demonstrates a product is appropriate for the protection of public health.

The laboratory, opened and operated by SMOORE’s Analysis, Testing and Safety Assessment Center, provides all non-clinical evidence required to bring a new nicotine product to market, including material safety, HPHCs (hazardous components and potentially hazardous components), and toxicology testing.

This is the first PMTA testing laboratory to open in China, and will allow SMOORE and its flagship brand FEELM, the world’s leading closed vape system solution provider, to further improve the safety of their products, and help the brands they work with to successfully pass PMTA certification.

Prior to SMOORE opening its new laboratory, any vaping companies that wanted to enter the US would need to use third-party partners to complete their PMTA testing, which can be a costly and time-consuming process. With the new China facility, FEELM’s brand partners can more easily complete their PMTA certification and improve their accessibility to the US market.

Dr Long, the director of SMOORE’s new Safety Assessment Center, said:

“The FDA is very concerned about HPHCs and has set out a list of 33 substances which must be tested for.

“Our new laboratory can do all this and more, and has the capacity to test for 37 substances; we are the only facility in China whose testing capabilities covers the full range of HPHCs substances.”

The laboratory tests against a world-leading new database of HPHCs, developed by SMOORE, and derived from international toxicity databases including the US Environmental Protection Agency (EPA).

Advanced computational toxicology software is also used to predict for unknown and potentially hazardous ingredients not included in these databases, further increasing SMOORE’s safety assessments.

Since establishing its first research institute in 2017, SMOORE has continued to lead the industry in evidence-based research. Its Safety Assessment Center has raised safety standards to medical grade, and works to constantly review product safety.

A total of eight products have been approved for marketing by the FDA, many of which are manufactured by SMOORE, demonstrating that the FDA approves of the processes and testing mechanisms deployed in SMOORE’s new laboratory in China.

SMOORE is now working with its brand partners and FEELM clients to expand its testing and to provide greater support for product design and is issuing the relevant safety reports.

SMOORE is determined to become the driving force behind supporting brands in their engagement with the FDA and other regulatory agencies, empowering them to enter more overseas markets.

NOTES FOR EDITORS

For more information on the PMTA process: fda.gov/tobacco-products/market-and-distribute-tobacco-product/premarket-tobacco-product-applications

About FEELM:

As a flagship tech brand belonging to SMOORE, FEELM is the world’s leading closed vape system solution provider. Based on the world's leading Ceramic Coil Heating Technology, FEELM combines authentic Flavor Reproduction Technology with innovative electronics technology, bringing ultimate sensation and premium vaping experience.

About SMOORE:

SMOORE is a global leader in offering vaping technology solutions, including manufacturing vaping devices, and vaping components for HNB products on an ODM basis, with advanced R&D technology, strong manufacturing capacity, wide-spectrum product portfolio and diverse customer base.

According to Frost & Sullivan, SMOORE is the world’s largest vaping device manufacturer in terms of revenue, accounting for 22.8% of the total global market share in 2021 . Its global market share is bigger than the sum of those listed from No.2 to No.5.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Westlake Expands Global Chlorovinyls Manufacturing Capacity With Acquisition of PVC and VCM Plants in Wilhelmshaven, Germany15.6.2026 20:18:00 CEST | Press release

Westlake Corporation (NYSE: WLK) (“Westlake”) announced today that its German subsidiary, Westlake Vinnolit GmbH & Co. KG, has completed the previously-announced acquisition of a polyvinyl chloride and vinyl chloride monomer production site located in Wilhelmshaven, Germany (the “Wilhelmshaven plant”). The Wilhelmshaven plant, which was previously in insolvency administration, has the capacity to produce 380,000 metric tons of PVC per year. “This acquisition strengthens our Performance & Essential Materials business by expanding our global chlorovinyls manufacturing footprint and complements our existing chlorovinyl production facilities in Europe and North America,” said Jean-Marc Gilson, President and Chief Executive Officer of Westlake. “The Wilhelmshaven plant, which is located in Lower Saxony on Germany’s North Sea coast, benefits from advantageous logistical infrastructure, including a deep-water dock that enables efficient raw-materials supply. We look forward to welcoming the s

Onera Announces Integration of the Onera hPSG® Solution With Somnoware15.6.2026 19:35:00 CEST | Press release

Onera hPSG®, an end-to-end home polysomnography solution from Onera Health, is now integrated into Somnoware, enabling their customers to conduct Polysomnography tests (PSGs) in the patient's home while managing the entire workflow in Somnoware. Onera Health, a leader in transforming sleep medicine, announces that its end-to-end home polysomnography solution, the Onera hPSG® solution, now integrates with Somnoware by ResMed sleep lab management software. This integration enables clinicians to conduct Polysomnography tests (PSGs) where patients sleep most comfortably, in their own home, while managing the entire workflow in Somnoware. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615106079/en/ Onera hPSG®, an end-to-end home polysomnography solution from Onera Health, is now integrated into Somnoware, enabling their shared customers to conduct Polysomnography tests (PSGs) in the patient's home while managing the entire wo

Digital Cooperation Organization Launches Global Expert Community to Accelerate International Digital Cooperation15.6.2026 18:18:00 CEST | Press release

A global platform mobilizing expertise and collective action to advance shared digital priorities The Digital Cooperation Organization (DCO), the world's first standalone international organization dedicated to inclusive and sustainable digital economy growth, today announced the launch of the Global Expert Community (GEC) — a new platform designed to mobilize expertise and advance international collaboration in support of high-impact digital initiatives across DCO Member States and beyond. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615565781/en/ Digital Cooperation Organization Launches Global Expert Community to Accelerate International Digital Cooperation (Graphic: AETOSWire) The GEC reflects the DCO's continued commitment to turning digital cooperation into action by expanding access to specialized expertise and strengthening collaboration across sectors and borders. As digital transformation reshapes economies an

New Pivotal Study Data Show Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 115.6.2026 18:00:00 CEST | Press release

- Secondary and Exploratory Endpoint Results from Phase 3 Studies Presented at SLEEP 2026 Underscore Improvements with Oveporexton Across a Broad Range of Daytime and Nighttime Symptoms - Takeda is on Track to Bring the First and Only Orexin Agonist to People Living with Narcolepsy Type 1 with Regulatory Submissions Under Review Takeda (TSE:4502/NYSE:TAK)today presented additional results from two pivotal studies at SLEEP 2026, showing oveporexton (TAK-861), an oral orexin receptor 2 (OX2R)-selective agonist, improved daily functioning as well as cognitive and sleep-related symptoms associated with narcolepsy type 1 (NT1).1,2,3 Oveporexton is designed to address the underlying orexin deficiency that causes NT1 by restoring orexin signaling. These data, along with previously disclosed Phase 3 results, demonstrated improvement across the broad disease spectrum, supporting the potential of oveporexton to redefine the standard of care for NT1.4 "Narcolepsy type 1 is a 24-hour disease drive

Boomi Named a Pioneer in June 2026 Gartner® Emerging Market Quadrant for No-Code Agent Builders15.6.2026 17:30:00 CEST | Press release

For Boomi, this recognition reinforces its vision and momentum in enterprise agentic AI Boomi, the data activation company for AI, today announced it has been recognized as aPioneer in the Gartner® Emerging Market Quadrant for No-Code Agent Builders (NCAB). Gartner defines the NCABs market as SaaS-delivered products that offer an integrated design and runtime environment to build, publish and manage AI-powered agents without using coding. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615413216/en/ Boomi Named a Pioneer in June 2026 Gartner® Emerging Market Quadrant for No-Code Agent Builders Boomi sees this recognition as a reflection of the company's rapid evolution from an integration and automation powerhouse to a full-scale agentic infrastructure platform, expanding Boomi’s role in the emerging agentic AI market. A New Chapter in Enterprise Agentic AI According to Gartner, vendors recognized as a Pioneer in this quad

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye